Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

The inheritance of Apolipoprotein E4 (APOEε4) brings the highest genetic risk of Alzheimer's
disease (AD), arguably the highest genetic risk in human pathology. Since the discovery of …

Increasing evidence supports that age, APOE and sex interact to modulate Alzheimer's
disease (AD) risk, however the underlying pathways are unclear. One way that AD risk …

Alzheimer's disease (AD) is a prevalent neurodegenerative disease account for 60–80% of
the total number of people with dementia, but its treatment and prevention strategies are still …

Although substantial progress has been made in the last two decades, there are still
important unfilled gaps in the understanding of the pathomechanism of Alzheimer's disease …

Many studies aim to detect the early phase of dementia. One of the major ways to achieve
this is to identify corresponding biomarkers, particularly immune blood biomarkers. The …

Despite decades of intense research, disease-modifying therapeutic approaches for
Alzheimer's disease (AD) are still very much needed. Apart from the extensively analyzed …

Alzheimer's disease (AD) is a complex neurological ailment that causes cognitive decline
and memory loss. Cholesterol metabolism dysregulation has emerged as a crucial element …

Alzheimer's disease (AD) presents a multifactorial neurological disorder with multiple
enzyme involvement in its onset. Conventional monotherapies fall short in providing long …

Background: Age, genetic, and environmental factors are noted to contribute to dementia
risk. Neuroplasticity, protection from degeneration and cell death, and early intervention are …